Xenon Pharmaceuticals Files 8-K on Officer/Director Changes
Ticker: XENE · Form: 8-K · Filed: Dec 1, 2025 · CIK: 1582313
| Field | Detail |
|---|---|
| Company | Xenon Pharmaceuticals Inc. (XENE) |
| Form Type | 8-K |
| Filed Date | Dec 1, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
Xenon Pharma 8-K: Leadership changes and financial updates filed Nov 24.
AI Summary
Xenon Pharmaceuticals Inc. filed an 8-K on November 24, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Why It Matters
This filing provides updates on the company's leadership and governance structure, which can impact strategic direction and investor confidence.
Risk Assessment
Risk Level: low — This is a routine corporate filing detailing changes in directors and officers, not a material event like a product failure or major financial distress.
Key Players & Entities
- Xenon Pharmaceuticals Inc. (company) — Registrant
- November 24, 2025 (date) — Date of earliest event reported
- 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8 (address) — Principal Executive Offices
- (604) 484-3300 (phone_number) — Registrant's Telephone Number
FAQ
What specific officer or director positions were affected by the changes reported in this 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and positions are not detailed in the provided excerpt.
Are there any details about new compensatory arrangements for officers mentioned in the filing?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item of information, but the specifics of these arrangements are not included in the provided text.
What is the significance of the 'Financial Statements and Exhibits' being filed?
The inclusion of 'Financial Statements and Exhibits' suggests that the company is providing updated financial information or supporting documents alongside the corporate governance updates.
When was this 8-K report officially filed with the SEC?
The filing was made on December 1, 2025, with the earliest event reported being November 24, 2025.
What is Xenon Pharmaceuticals Inc.'s primary industry classification?
Xenon Pharmaceuticals Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 582 words · 2 min read · ~2 pages · Grade level 13.4 · Accepted 2025-12-01 16:05:34
Filing Documents
- xene-20251124.htm (8-K) — 44KB
- xene-ex10_1.htm (EX-10.1) — 504KB
- 0001193125-25-303862.txt ( ) — 724KB
- xene-20251124.xsd (EX-101.SCH) — 25KB
- xene-20251124_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Amended and Restated 2025 Inducement Equity Plan and related form agreements. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XENON PHARMACEUTICALS INC. Date: December 1, 2025 By: /s/ Thomas P. Kelly Thomas P. Kelly Chief Financial Officer